Haleon (HLN) Set to Announce Quarterly Earnings on Thursday

by · The Markets Daily

Haleon (NYSE:HLN – Get Free Report) will release its earnings data before the market opens on Thursday, October 31st. Analysts expect Haleon to post earnings of $0.11 per share for the quarter.

Haleon (NYSE:HLN – Get Free Report) last released its quarterly earnings data on Thursday, August 1st. The company reported $0.08 earnings per share for the quarter, missing the consensus estimate of $0.09 by ($0.01). Haleon had a net margin of 9.71% and a return on equity of 13.15%. The company had revenue of $3.50 billion during the quarter, compared to the consensus estimate of $3.55 billion. During the same quarter in the prior year, the firm earned $0.08 EPS. On average, analysts expect Haleon to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Haleon Trading Down 0.7 %

HLN opened at $9.92 on Wednesday. The company has a fifty day moving average price of $10.24 and a two-hundred day moving average price of $9.23. Haleon has a 1-year low of $7.70 and a 1-year high of $10.80. The company has a market cap of $45.27 billion, a P/E ratio of 33.05, a price-to-earnings-growth ratio of 2.90 and a beta of 0.26. The company has a current ratio of 0.84, a quick ratio of 0.58 and a debt-to-equity ratio of 0.44.

Haleon Cuts Dividend

The company also recently declared a semi-annual dividend, which was paid on Thursday, September 19th. Investors of record on Friday, August 16th were paid a dividend of $0.0514 per share. This represents a yield of 1.6%. The ex-dividend date of this dividend was Friday, August 16th. Haleon’s dividend payout ratio (DPR) is currently 33.33%.

Analysts Set New Price Targets

A number of equities research analysts have commented on the company. UBS Group raised Haleon to a “strong-buy” rating in a research note on Tuesday, October 1st. Morgan Stanley lifted their target price on shares of Haleon from $9.90 to $10.95 and gave the stock an “overweight” rating in a research report on Friday, September 20th. The Goldman Sachs Group downgraded Haleon from a “buy” rating to a “neutral” rating in a research report on Tuesday, August 6th. Finally, Berenberg Bank began coverage on shares of Haleon in a report on Tuesday, August 6th. They set a “buy” rating for the company. One investment analyst has rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Haleon currently has a consensus rating of “Buy” and an average target price of $10.95.

Check Out Our Latest Stock Analysis on HLN

About Haleon

(Get Free Report)

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.

Featured Stories